Cancer Immunotherapy ETF is on the Way

There are currently eight dedicated, non-leveraged biotechnology exchange traded funds on the market. That number could grow by at least one if the Loncar Cancer Immunotherapy ETF comes to market. Kansas-based Loncar Investments said in a statement out Monday that it is partnering with ETF-in-a-box...